Suven Life Sciences Ltd has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs).
A patent is a grant made by a government that confers upon the creator of an invention the sole right to make, use, and sell that invention for a set period of time.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
"They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia" Suven said in a release on Tuesday.
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico.
The patents may be out-licensed at phase 1 or phase 2 of clinical development, as they are the exclusive products of Suven. These patents are valid till 2029.